Report Company Directory

AB INTL GROUP CORP

• ABQQ Announces Its Subsidiary AI+ Hubs Corp Acquires ufilm AI Intellectual Property, Ushering in a New Era of IP Licensing by GlobeNewsWire
• AB INTL GROUP Reports of Financial Results for period ending February 28, 2025, and consistent achieved Net Profitability by GlobeNewsWire
• AB INTL Group Announces Repurchase of 300 Million Shares and Planning Spin-off of NFT MMM IP and AI Consulting Business by GlobeNewsWire
• ABQQ Reports FY 2024 Audited Financial Results, Introduces FY 2025 Outlook, Announces to Repurchase $5 Million of Shares by Year-End 2025 by GlobeNewsWire
• AB INTL GROUP Announces Launch of a Film Entity as Subsidiary in China by GlobeNewsWire
• AB INTL GROUP Announces Repurchase of Common Stock for Cancelation by GlobeNewsWire
• AB INTL GROUP Announces Business Updates by GlobeNewsWire
• AB INTL GROUP Reports of Financial Results for period ending May 31, 2024 and achieved Net Profitability by GlobeNewsWire
• AB INTL GROUP Announced Fencing Film “THE ONE” Premiere for Screening on Cinemas in China by GlobeNewsWire
• AB INTL Reports Forecast Revenues from Its Participated Chinese Market Film Sales by GlobeNewsWire

AB SA

• AB SA: 2 directors by SmartInsider
• INFORME DIARIO 28 OCTUBRE + RDOS. ESPAÑA Y EUROPA 3T’22. IDEAS DESTACADAS Y PREVIEWS (ANÁLISIS BANCO SABADELL) by Sabadell
• AB INBEV: Divesting its stake in the Russian JV with Anadolu Efes | BUY TOP PICKS | EUR65 by Bryan Garnier
• Morning Note: ABI BB, AGFB BB, AKZA NA, ELI BB, FLOW NA, FUR NA, GIMB BB, PROX BB, QFG BB, WDP BB by KBC Securities
• KBC Securities Morning Note 14-3-2022 ABI BB, MTLS US by KBC Securities
• Morning Note: ABI BB, ASRNL NA, GREEN BB, IVA FP, REC BB, SEQUA BB by KBC Securities
• Morning Note; ABI BB, GREEN BB, INTER EN, KPN NA, SEQUA BB, UMI BB by KBC Securities
• AB INBEV - Investor seminar brings fresh 4-8% medium term EBITDA growth guidance ABI BB by KBC Securities
• AB INBEV - BUY | EUR65 (+25%) Investor day feedback: a future of more cheers? by Bryan Garnier
• Dynamic Top Pick List - Update December 2021 by KBC Securities

AB Sagax Class B

• Weekly Real Estate Matrix by ABG Sundal Collier
• Sagax – Buy/SEK 285: Accelerating growth by Nordea
• Weekly Real Estate Matrix by ABG Sundal Collier
• New sheriffs in town by ABG Sundal Collier
• More M&A required by ABG Sundal Collier
• Weekly Real Estate Matrix by ABG Sundal Collier
• Weekly Real Estate Matrix by ABG Sundal Collier
• Weekly Real Estate Matrix by ABG Sundal Collier
• Weekly Real Estate Matrix by ABG Sundal Collier
• Weekly Real Estate Matrix by ABG Sundal Collier

AB Science SA

• AB Science reçoit un avis d'autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant by GlobeNewsWire
• AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer by GlobeNewsWire
• INVEST SECURITIES - AB SCIENCE : Un nouvel axe autour du AB8939 - ACHAT, OC 2,7€ vs 2,5€ by Invest Securities
• AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041 by GlobeNewsWire
• AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041 by GlobeNewsWire
• AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1 by GlobeNewsWire
• AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia by GlobeNewsWire
• Le brevet pour le masitinib dans le traitement de la drépanocyose a été officiellement accordé aux Etats-Unis avec une protection jusqu'en 2040 by GlobeNewsWire
• AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040 by GlobeNewsWire
• AB Science annonce l’initiation de la couverture de son titre par Maxim Group avec un objectif de cours de 4,0 euros par action by GlobeNewsWire

AB SMALL CAP CORE PORTFOLIO